Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot pharmacokinetic and safety study of AD-229 in healthy adults
TCTR20261015008Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rebamipide (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Rebamipide Cmax and Rebamipide AUC. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
rebamipide
Beyond the preview
Go deeper on TCTR20261015008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261015008.